The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier ...

The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...

Amgen Inc. (AMGN), incorporated in 1980 and headquartered in Thousand Oaks, California, is a biotech titan that crafts ...

AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested ...

Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...

Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

High-yield bargain opportunities exist for disciplined, value-focused investors. Read more about the two standout stocks I've ...

Evercore ISI analyst Umer Raffat maintained a Buy rating on Amgen (AMGN – Research Report) today. The company’s shares closed last Friday at ...

Goldman Sachs analysts removed Amgen (AMGN) from the firm’s US Conviction List as part of its monthly update.Don't Miss our Black Friday ...

The biotech industry can be volatile even for relatively large companies. Amgen (NASDAQ: AMGN), one of the more prominent ...

The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...